AstraZeneca has announced that it will showcase five real-world evidence (RWE) studies from its cardiovascular, renal and metabolism (CVRM) portfolio, reinforcing its commitment, it says, to advancing science in chronic kidney disease (CKD) and hyperkalaemia, at the National Kidney Foundation (NKF) Spring Clinical Meeting (11–15 April, Austin, USA).
AstraZeneca will present data from the REVOLUTIONIZE I RWE study that show the recurrent nature of hyperkalaemia in patients with CKD and demonstrate the unmet need for these patients.
REVOLUTIONIZE I was a retrospective, observational, RWE study of US electronic health records that evaluated the recurrence of hyperkalaemia following a medical nutrition therapy (MNT) visit, also referred to as dietary counselling, in 2,048 adults with hyperkalaemia and Stage 3 or 4 CKD. Patients were followed up for six months post-MNT and were censored when they died or initiated outpatient potassium binder therapy. The study found that the percentage of patients with CKD Stage 3/4 who had recurrent hyperkalaemia increased from one month (37.4%) to six months (56%).
When looking at the patient population from first hyperkalaemia recurrence (n=842) to the fourth hyperkalaemia recurrence (n=204), the average time between recurrences progressively decreased to less than 30 days over time (from 45 days to 27 days) and the percentage of patients with hyperkalaemia recurrence increased in those with a prior recurrence (from 56% to 70%) during the six-month follow up post-MNT. The RWE study, an AstraZeneca press release states, highlights an unmet need for an oral anti-hyperkalaemia therapy for treating patients with the condition.
The REVOLUTIONIZE RWE is part of the CRYSTALIZE evidence program, which is comprised of over 50 clinical and RWE studies researching the potential role of the drug LOKELMA in the management of hyperkalaemia across the cardiorenal spectrum.